



# EHA 2025 Congress

June 12–15, 2025  
Milan, Italy



## TOP ABSTRACTS

To help navigate the exciting content being presented at the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

# EHA 2025: Top abstracts in lymphoma and CLL

June 12–15, 2025

Thursday, June 12			
Abstract	Title	Speaker	Time (CEST)
<b>S190</b> <a href="#">View</a>	Cyclophosphamide is superior to methotrexate in previously untreated large granular lymphocyte leukemia. Final results of a prospective, multicentric, phase II randomized controlled trial CT01976182	Thierry Lamy	17:00–17:15
<b>S191</b> <a href="#">View</a>	The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia: Final analysis from the phase 3 GAIA/CLL13 trial	Moritz Fürstenau	17:15–17:30
<b>S225</b> <a href="#">View</a>	Acimtamig (AFM13) in combination with AlloNK® (AB-101) in patients with relapsed or refractory classical Hodgkin lymphoma: Results from the dose finding phase of the LuminICE-203 phase 2 study	Amitkumar Mehta	17:00–17:15
<b>S226</b> <a href="#">View</a>	Long-term responses and late toxicities in advanced-stage Hodgkin lymphoma: A 10-year update of the HD0607 trial	Alessandro Cellini	17:15–17:30
<b>S229</b> <a href="#">View</a>	Elevated serum TARC after one cycle of BV-AVD correlates with adverse prognosis despite escalation to BrECADD in advanced stage Hodgkin lymphoma: Biomarker analysis from the EORTC-1537-COBRA trial	Sophie Teesink	18:00–18:15
<b>S240</b> <a href="#">View</a>	Prospective validation of end of treatment ctDNA-MRD BY PhaseD-Seq in DLBCL patients from a national HOVON trial	Martine Chamuleau	17:00–17:15
<b>S241</b> <a href="#">View</a>	Frail is not fail: Comorbidities do not affect non-relapse mortality and safety in patients with LBCL treated with CAR-T therapy	Eugenio Galli	17:15–17:30

Friday, June 13			
Abstract	Title	Speaker	Time (CEST)
<b>S235</b> <a href="#">View</a>	Long-term efficacy and survival outcomes with odronextamab for patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): 2-year follow-up from the phase 2 ELM-2 study	Stefano Luminari	17:00–17:15
<b>S236</b> <a href="#">View</a>	A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory B-cell lymphoma	Saurabh Dahiya	17:15–17:30
<b>S237</b> <a href="#">View</a>	Real-world effectiveness and safety outcomes among key subgroups of second-line (2L) axicabtagene ciloleucel (axi-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)	Dasom Lee	17:30–17:45
<b>S238</b> <a href="#">View</a>	High CD70 expression in newly diagnosed follicular lymphoma is linked to relapse and presents opportunities for dual CD19-CD70 CAR-T therapy	Maria Ros	17:45–18:00
<b>S239</b> <a href="#">View</a>	A global phase 1b study of JNJ-90014496, a CD19/CD20 bi-specific chimeric antigen receptor (CAR) T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)	Matthew Ku	18:00–18:15

Saturday, June 14			
Abstract	Title	Speaker	Time (CEST)
<b>S101</b> <a href="#">View</a>	Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the randomized phase III POLARGO trial	Matthew Matasar	12:00–12:15
<b>S104</b> <a href="#">View</a>	Minor independent clones in patients with chronic lymphocytic leukemia have a CLL-biased biological signature: Implications for disease ontogeny and evolution	Ian Márquez-López	12:45–13:00
<b>S230</b> <a href="#">View</a>	Tafasitamab (tafa) plus lenalidomide (len) and rituximab (R) for patients with relapsed or refractory follicular lymphoma (R/R FL): Results from the phase 3 inMIND study	Marek Trneny	17:15–17:30
<b>S231</b> <a href="#">View</a>	Updated efficacy & safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia (WM): Ongoing phase (Ph) 1 CaDAnCe-101 study results	Anna Maria Frustaci	17:30–17:45
<b>S232</b> <a href="#">View</a>	MorningSun: Open-label phase II trial of the efficacy and safety of subcutaneous mosunetuzumab (Mosun SC) as frontline (1L) treatment in symptomatic patients with marginal zone lymphoma (MZL)	John M. Burke	17:45–18:00
<b>S233</b> <a href="#">View</a>	Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial	Martin Dreyling	17:00–17:15
<b>S234</b> <a href="#">View</a>	Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma	Raul Cordoba	18:00–18:15

Sunday, June 15			
Abstract	Title	Speaker	Time (CEST)
<b>LB4003</b> <a href="#">View</a>	Transcriptional reprogramming and survival co-dependencies of chronic lymphocytic leukemia resistant to venetoclax	Daisy Diaz Rohena	09:45–10:00
<b>S155</b> <a href="#">View</a>	Ibrutinib plus venetoclax with MRD-guided duration of treatment is superior to both continuous ibrutinib monotherapy and FCR for previously untreated CLL: Report of the phase III UK FLAIR study	Talha Munir	11:00–11:15
<b>S156</b> <a href="#">View</a>	Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study	Paolo Ghia	11:15–11:30
<b>S158</b> <a href="#">View</a>	Updated efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: Results from the ongoing phase (ph) 1 CaDAnCe-101 study	Lydia Scarfò	11:45–12:00
<b>S159</b> <a href="#">View</a>	Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responses	Chan Cheah	12:00–12:15
<b>S245</b> <a href="#">View</a>	First disclosure of epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2	Raul Cordoba	11:00–11:15
<b>S246</b> <a href="#">View</a>	A pivotal study of SHR2554, an oral inhibitor against enhancer of zeste homolog 2 (EZH2), in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL)	Yubin Song	11:15–11:30
<b>S247</b> <a href="#">View</a>	Durable efficacy with fixed-duration epcoritamab + polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) for 1L diffuse large b-cell lymphoma (EPCORE NHL-5)	Daniel Kerr	11:30–11:45
<b>S248</b> <a href="#">View</a>	Frontline phase II rituximab-polatuzumab-glofitmab (R-Pola-Glo) trial demonstrates a manageable safety profile and high response rates in elderly and medical unfit patients with aggressive lymphoma	Thomas Melchardt	11:45–12:00
<b>S249</b> <a href="#">View</a>	Excellent outcome with interim PET adapted treatment reduction in elderly DLBCL pts with favourable prognosis: Results of 288 pts treated in optimal>60 trial of the DSHNHL/GLA	Viola Pöschel	12:00–12:15
<b>S280</b> <a href="#">View</a>	Enhanced CAR T-cell expansion and durable complete responses with NKTR-255 plus lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma	Alexandre Hirayama	11:00–11:15
<b>S281</b> <a href="#">View</a>	Low rates of high-grade toxicities with GLPG5101, a fresh, stem-like, early memory phenotype anti-CD19 CAR T-cell therapy in patients with non-Hodgkin lymphoma in the ATALANTA-1 study	Pim G. N. J. Mutsaers	11:15–11:30

Posters			
Abstract	Title	Speaker	Time (CEST)
<b>PF572</b> <a href="#">View</a>	Measurable residual disease kinetics with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia: Data from the phase 3 AMPLIFY trial	Paolo Ghia	Friday, 18:30
<b>PF869</b> <a href="#">View</a>	PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: Long-term follow-up of the GATLA LH-05 trial	Astrid Pavlovsky	Friday, 18:30
<b>PS1565</b> <a href="#">View</a>	SEQUOIA 5-year follow-up in Arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)	Mazyar Shadman	Saturday, 18:30
<b>PS1866</b> <a href="#">View</a>	Real-world evidence of brentuximab vedotin (BV) consolidation after autologous transplant (ASCT) in relapsed/refractory Hodgkin lymphoma (RRHL): 2-year follow-up of GATLA RRHL study	Astrid Pavlovsky	Saturday, 18:30
<b>PS1870</b> <a href="#">View</a>	PD-1-based salvage therapy for relapsed and refractory Hodgkin lymphoma: A multicenter real-world analysis	Hishan Tharmaseelan	Saturday, 18:30
<b>PS1898</b> <a href="#">View</a>	Patient-reported outcomes in patients with relapsed/refractory follicular lymphoma treated with epcoritamab within the entire study cohort and in patients with symptoms at baseline	P. Connor Johnson	Saturday, 18:30
<b>PS1909</b> <a href="#">View</a>	Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO	Gareth Gregory	Saturday, 18:30
<b>PS1957</b> <a href="#">View</a>	Updated safety run-in results from LOTIS-5: A phase 3, randomized trial of loncastuximab tesirine with rituximab versus immunochemotherapy in patients with R/R DLBCL/HGBL	Carmelo Carlo-Stella	Saturday, 18:30
<b>PS1968</b> <a href="#">View</a>	Match-adjusted comparative analysis of epcoritamab + R-DHAX/C or R-ICE vs R-DHAX/C or R-ICE in 2L+ transplant-eligible patients with diffuse large B-cell lymphoma	Justin Darrah	Saturday, 18:30
<b>PS2150</b> <a href="#">View</a>	4-year update of phase 2 ELARA trial: Clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (R/R FL)	Catherine Thieblemont	Saturday, 18:30





**#EHA2025**

Follow us on X to keep up to date  
with the latest from the congress

**@lymphomahub**



Brought to you by

